# Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

> **NCT00091156** · PHASE3 · TERMINATED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 598 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** gefitinib
- **PROCEDURE:** adjuvant therapy

## Key facts

- **NCT ID:** NCT00091156
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-05
- **Primary completion:** 2008-07
- **Final completion:** —
- **Target enrollment:** 598 (ESTIMATED)
- **Why stopped:** low accrual
- **Last updated:** 2012-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00091156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00091156, "Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00091156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*